2 天之前 · BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has …

2 天之前 · The FDA approved Journavx (suzetrigine) 50 mg oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain in adults.

FDA Approves Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain. BOSTON--(BUSINESS WIRE)--Jan. 30, 2025-- Vertex Pharmaceuticals …

1 天前 · BOSTON, January 30, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved …

1 天前 · The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication …

1 天前 · It will be sold under the brand name Journavx. A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. ... acting director of the …

1 天前 · BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved …

1 天前 · FDA approves new, non-opioid painkiller Journavx The drug represents the first new class of pain medication in decades. January 30, 2025 at 7:28 p.m. EST Just now

1 天前 · Nonetheless, Vertex executives say Journavx’s ability to soothe pain without the risk of addiction will likely make it a blockbuster, a drug that generates sales of at least $1 billion a year.

1 天前 · Vertex wins FDA approval for non-opioid pain drug, setting stage for closely watched rollout ... Journavx has been priced at $31 a day. Market analysts have forecasted the drug …